**About Hemofarm**

**Hemofarm in Obninsk** is a production site of STADA international pharmaceutical group.

STADA has more than 125-year history and acts in accordance with its purpose "Caring for people’s health as a trusted partner".

STADA focuses on the internationalization of its production and business, while remaining a local market player in each region. Today, STADA has **one of the deepest** **levels of localization – more than 65%,** and continues investing in this direction.

STADA Group includes more than 20 production facilities worldwide, including Hemofarm site.

Hemofarm site **was built in 2006** in line with the Good Manufacturing Practice (GMP) requirements, including zoning of facilities and organization of personnel and material flows. The total **area of production facilities is 12,300 m2,** the area of the production unit is about 5,800 m2. The production process is arranged based on the modern high-tech equipment from leading world manufacturers.

Hemofarm production site became **part of STADA in 2010**. This is the first large-scale foreign production established in the Obninsk municipal industrial zone from which the industrial parks of the Kaluga Region grew later.

Hemofarm site **specializes in the production of solid dosage forms** (tablets, capsules). The plant produces drugs for gastrointestinal, cardiovascular and respiratory diseases, as well as antihistamines and non-steroidal anti-inflammatory drugs. **75% of the products manufactured at the site are included in the Essential Drugs List.** The production capacity is 46.5 mio packs per year.

In 2022, it is planned to finalize the technology transfer for the medicines which are now produced at the Takeda manufacturing sites in Ireland and Germany, to STADA Russian production site in Obninsk - Hemofarm. This means about 6 products with a production volume of up to 13 mio packs per year.

**In October 2007**, an RP Darmstadt inspection was held at Hemofarm, as a result of which **the site received a GMP Certificate** authorizing the company to export medicines produced in Obninsk to the EU countries. From 2007 to the present, Hemofarm has been constantly confirming the validity of this Certificate.

According to the voluntary environmental rating, Hemofarm site has been repeatedly **recognized as the most environmentally efficient enterprise** of the Kaluga region.

Today, Hemofarm site in Obninsk **employs about 200 people**, and manufactures such STADA products as: **Diclofenac, Esslidin, Enalapril, Lavomax, Indapamide, Ibuprofen, etc.**